Lowest Price Guaranteed
Pages
641
Last Updated
September 2026
View Count
47412
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of T-cell Immunotherapies
6.2.1. Historical Evolution
6.2.2. Key Considerations for Developing T-cell Immunotherapies
6.2.3. Strategies Employed for the Redirection of T-cells
6.2.4. Manufacturing of Engineered T-cells
6.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
6.3.1. Development History
6.3.2. Structure of CAR
6.3.2.1. Ectodomain
6.3.2.2. Transmembrane (TM) Domain
6.3.2.3. Endodomain
6.3.3. Development of CAR-T Cells
6.3.4. Universal CAR-T Cells
6.3.5. Route of Administration
6.3.6. Challenges Associated with CAR-T Cell Therapies
6.3.6.1. Competitive Risks
6.3.6.2. Clinical Risks
6.3.6.3. Regulatory Risks
6.3.6.4. Commercial Risks
6.4. Concluding Remarks
7. CAR-T CELL THERAPIES: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Type of Therapy
7.2.3. Analysis by Target Antigen
7.2.4. Analysis by Target Indication
7.2.5. Analysis by Therapeutic Area
7.2.6. Analysis by Stage of Development and Therapeutic Area
7.2.7. Analysis by Source of T-cells
7.2.8. Analysis by Stage of Development and Source of T-cells
7.2.9. Analysis by Route of Administration
7.2.10. Analysis by Dosage Regimen
7.2.11. Analysis by Target Patient Population
7.2.12. Most Active Industry Players: Analysis by Number of Therapies
7.2.13. Most Active Non-Industry Players: Analysis by Number of Therapies
7.3. CAR-T Cell Therapies: Overall Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
8. KEY INSIGHTS
8.1. Chapter Overview
8.2. CAR-T Cell Therapies: Popular Target Antigens
8.2.1. Popular Targets for Hematological Malignancies
8.2.2. Popular Targets for Solid Tumors
8.3. CAR-T Therapies: CAR Construct Analysis
8.3.1. Analysis by Generation of CAR
8.3.2. Analysis by Type of scFv Antibody Used
8.3.3. Analysis by Type of Virus Used
8.3.4. Analysis by Type of Gene Transfer Method Used
8.3.5. Analysis by Type of Co-Stimulatory Domain
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. CAR-T Cell Therapies: Clinical Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
9.3.3. Analysis by Trial Phase
9.3.4. Analysis of Enrolled Patient Population by Trial Phase
9.3.5. Analysis by Trial Registration Year and Trial Phase
9.3.6. Analysis by Trial Status
9.3.7. Analysis by Patient Gender
9.3.8. Analysis by Therapeutic Area
9.3.9. Analysis by Study Design
9.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
9.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
9.3.12. Analysis by Geography
10. KEY OPINION LEADERS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. CAR-T Cell Therapies: Key Opinion Leaders
10.4.1. Analysis by Type of Organization
10.4.2. Analysis by Affiliated Organization
10.4.3. Analysis by Geographical Location of KOLs
10.4.4. KOL Activeness versus KOL Strength
10.4.5. Most Prominent KOLs: Analysis by RA score
10.4.6. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
11. COMPANY PROFILES
11.1. Chapter Overview
11.2. Autolus
11.3. Bluebird Bio
11.4. Bristol Myers Squibb
11.5. CARsgen Therapeutics
11.6. Cellectis
11.7. Gilead Sciences
11.8. Innovative Cellular Therapeutics
11.9. Noile-Immune Biotech
11.10. Novartis
11.11. Sinobioway Cell Therapy
11.12. Takara Bio
11.13. Wellington Zhaotai Therapies
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. CAR-T Cell Therapies: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Type of Partner
12.3.5. Most Popular Therapies: Analysis by Number of Partnerships
12.3.6. Most Active Industry Players: Analysis by Number of Partnerships
12.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
12.3.8. Analysis by Geography
12.3.8.1. Intercontinental and Intracontinental Agreements
12.3.8.2. International and Local Agreements
13. FUNDING AND INVESTMENTS ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. CAR-T Cell Therapies: Funding and Investment Analysis
13.3.1. Analysis by Year of Funding
13.3.2. Analysis of Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Amount Invested and Type of Funding
13.3.5. Analysis of Amount Invested by Year and Type of Funding
13.3.6. Analysis by Type of Investor
13.3.7. Analysis by Geography
13.3.8. Most Active Players
13.3.9. Leading Investors: Analysis by Number of Funding Instances
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. CAR-T Cell Therapies: Patent Analysis
14.3.1. Analysis by Patent Publication Year
14.3.2. Analysis by Patent Application Year
14.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
14.3.4. Analysis by Patent Jurisdiction
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.3.8. Leading Non-Industry Players: Analysis by Number of Patents
14.3.9. Leading Patent Assignees: Analysis by Number of Patents
14.4. Patent Benchmarking Analysis
14.4.1. Analysis by Patent Characteristics
14.5. Patent Valuation
14.6. Leading Patents by Number of Citations
15. CASE STUDY: CELL THERAPY MANUFACTURING
15.1. Chapter Overview
15.2. Overview of Cell Therapy Manufacturing
15.3. Cell Therapy Manufacturing Models
15.3.1. Centralized Manufacturing Model
15.3.2. Decentralized Manufacturing Model
15.4. Scalability of Cell Therapy Manufacturing Processes
15.4.1. Scale-Up
15.4.2. Scale-Out
15.5. Types of Cell Therapy Manufacturers
15.6. Key Challenges Related to Manufacturing of Cell Therapies
15.7. Key Considerations for Cell Therapy Manufacturing
15.7.1. Characterization
15.7.2. Cost of Goods
15.8. Automation of Cell Therapy Manufacturing Process
15.9. Cell Therapy Manufacturing Supply Chain
15.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
15.11. Regulatory Landscape
15.12. Future Perspectives
16. COST PRICE ANALYSIS
16.1. Chapter Overview
16.2. Factors Contributing to the High Price of Cell / Gene Therapies
16.3. Pricing Models for T-cell Immunotherapies
16.3.1. Based on Associated Costs
16.3.2. Based on Availability of Competing Products
16.3.3. Based on Patient Population
16.3.4. Based on Opinions of Industry Experts
16.4. Reimbursement related Considerations for T-cell Immunotherapies
16.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies
17. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
17.1. Chapter Overview
17.2. Market Drivers
17.3. Market Restraints
17.4. Market Opportunities
17.5. Market Challenges
17.6. Conclusion
18. GLOBAL CAR-T CELL THERAPY MARKET
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Global CAR-T Cell Therapy Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
18.4. Scenario Analysis
18.4.1. Conservative Scenario
18.4.2. Optimistic Scenario
18.5. Key Market Segmentations
19. CAR-T CELL THERAPY MARKET, BY PRODUCT
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. CAR-T Cell Therapy Market: Distribution by Product
19.3.1. CAR-T Cell Therapy Market for Abecma: Forecasted Estimates (till 2035)
19.3.2. CAR-T Cell Therapy Market for Breyanzi: Forecasted Estimates (till 2035)
19.3.3. CAR-T Cell Therapy Market for Carvykti: Forecasted Estimates (till 2035)
19.3.4. CAR-T Cell Therapy Market for Kymriah: Forecasted Estimates (till 2035)
19.3.5. CAR-T Cell Therapy Market for Tecartus: Forecasted Estimates (till 2035)
19.3.6. CAR-T Cell Therapy Market for Yescarta: Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation
20. CAR-T CELL THERAPY MARKET, BY TYPE OF THERAPY
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. CAR-T Cell Therapy Market: Distribution by Type of Therapy
20.3.1. CAR-T Cell Therapy Market for Autologous CAR-T Cell Therapy: Forecasted Estimates (till 2035)
20.3.2. CAR-T Cell Therapy Market for Allogeneic CAR-T Cell Therapy: Forecasted Estimates (till 2035)
20.4. Data Triangulation and Validation
21. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. CAR-T Cell Therapy Market: Distribution by Target Antigen
21.3.1. CAR-T Cell Therapy Market for CD19: Forecasted Estimates (till 2035)
21.3.2. CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (till 2035)
21.3.3. CAR-T Cell Therapy Market for CD20: Forecasted Estimates (till 2035)
21.3.4. CAR-T Cell Therapy Market for CD19/22: Forecasted Estimates (till 2035)
21.3.5. CAR-T Cell Therapy Market for Other Target Antigens: Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation
22. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. CAR-T Cell Therapy Market: Distribution by Target Indication
22.3.1. CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (till 2035)
22.3.2. CAR-T Cell Therapy Market for Large B-cell Lymphoma: Forecasted Estimates (till 2035)
22.3.3. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035)
22.3.4. CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (till 2035)
22.3.5. CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (till 2035)
22.3.6. CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035)
22.3.7. CAR-T Cell Therapy Market for Others: Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation
23. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY GEOGRAPHICAL REGIONS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions
23.3.1. CAR-T Cell Therapy Market in North America: Forecasted Estimates (till 2035)
23.3.2. CAR-T Cell Therapy Market in Europe: Forecasted Estimates (till 2035)
23.3.3. CAR-T Cell Therapy Market in Asia-Pacific: Forecasted Estimates (till 2035)
23.3.4. CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (till 2035)
23.3.5. CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (till 2035)
23.3.6. CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation
24. CAR-T CELL THERAPY MARKET, SALES FORECAST OF DRUGS
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Commercialized CAR-T Cell Therapies: Sales Forecast
24.4. Clinical CAR-T Cell Therapies: Sales Forecast
24.5. Data Triangulation and Validation
25. CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. CAR-T Cell Therapies: Leading Players
25.3.1. Gilead Sciences Sales Forecast
25.3.2. Bristol Myers Squibb Sales Forecast
25.3.3. Novartis Sales Forecast
25.3.4. Janssen Sales Forecast
25.3.5. JW Therapeutics Sales Forecast
25.4. Data Triangulation and Validation
26. PROMOTIONAL ANALYSIS
26.1. Chapter Overview
26.2. Channels Used for Promotional Campaigns
26.3. Summary of Product Website Analysis
26.4. Summary of Patient Support Services and Informative Downloads
26.5. Kymriah: Promotional Analysis
26.5.1. Drug Overview
26.5.2. Product Website Analysis
26.5.2.1. Message for Healthcare Professionals
26.5.2.2. Message for Patients
26.5.2.3. Informative Downloads
26.5.3. Patient Support Services
26.6. Yescarta: Promotional Analysis
26.6.1. Drug Overview
26.6.2. Product Website Analysis
26.6.2.1. Message for Healthcare Professionals
26.6.2.2. Message for Patients
26.6.2.3. Informative Downloads
26.6.3. Patient Support Services
26.7. Tecartus: Promotional Analysis
26.7.1. Drug Overview
26.7.2. Product Website Analysis
26.7.2.1. Message for Healthcare Professionals
26.7.2.2. Message for Patients
26.7.2.3. Informative Downloads
26.7.3. Patient Support Services
26.8. Breyanzi: Promotional Analysis
26.8.1. Drug Overview
26.8.2. Product Website Analysis
26.8.2.1. Message for Healthcare Professionals
26.8.2.2. Message for Patients
26.8.2.3. Informative Downloads
26.8.3. Patient Support Services
26.9. Abecma: Promotional Analysis
26.9.1. Drug Overview
26.9.2. Product Website Analysis
26.9.2.1. Message for Healthcare Professionals
26.9.2.2. Message for Patients
26.9.2.3. Informative Downloads
26.9.3. Patient Support Services
26.10. Carvykti: Promotional Analysis
26.10.1. Drug Overview
26.10.2. Product Website Analysis
26.10.2.1. Message for Healthcare Professionals
26.10.2.2. Message for Patients
26.10.2.3. Informative Downloads
26.10.3. Patient Support Services
27. EXECUTIVE INSIGHTS
27.1. Chapter Overview
27.2. Company A
27.2.1. Company Snapshot
27.2.2. Interview Transcript: Head of Corporate Communications and Investor Relations
27.3. Company B
27.3.1. Company Snapshot
27.3.2. Interview Transcript: Former Chief Executive Officer
27.4. Company C
27.4.1. Company Snapshot
27.4.2. Interview Transcript: Chief Executive Officer, Founder and Chairman
27.5. Company D
27.5.1. Company Snapshot
27.5.2. Interview Transcript: Former Chief Operating Officer
27.6. Company E
27.6.1. Company Snapshot
27.6.2. Interview Transcript: Former Vice President
27.7. Company F
27.7.1. Company Snapshot
27.7.2. Interview Transcript: Former Vice President, Immuno-Oncology
27.8. Company G
27.8.1. Company Snapshot
27.8.2. Interview Transcript: Director, Business Development
27.9. Company H
27.9.1. Company Snapshot
27.9.2. Interview Transcript: Former Competitive Intelligence Manager
27.10. Company I
27.10.1. Company Snapshot
27.10.2. Interview Transcript: Professor
27.11. Company J
27.11.1. Company Snapshot
27.11.2. Interview Transcript: Assistant Professor
27.12. Company K
27.12.1. Company Snapshot
27.12.2. Interview Transcript: Chief Executive Officer
27.13. Company L
27.13.1. Company Snapshot
27.13.2. Interview Transcript: Chief Executive Officer
27.14. Company M
27.14.1. Company Snapshot
27.14.2. Interview Transcript: Chief Executive Officer
27.15. Company N
27.15.1. Company Snapshot
27.15.2. Interview Transcript: Director
27.16. Company O
27.16.1. Company Snapshot
27.16.2. Interview Transcript: Clinical Director
27.17. Company P
27.17.1. Company Snapshot
27.17.2. Interview Transcript: Senior Vice President, Cell Therapy Franchise
27.18. Company Q
27.18.1. Company Snapshot
27.18.2. Interview Transcript: Executive Vice President of Research & Development and Chief Medical Officer
27.19. Company R
27.19.1. Company Snapshot
27.19.2. Interview Transcript: Vice Chair, Center for ImmunoTherapy & Precision Immuno-Oncology
27.20. Company S
27.20.1. Company Snapshot
27.20.2. Interview Transcript: Chief Medical & Development Officer
27.21. Company T
27.21.1. Company Snapshot
27.21.2. Interview Transcript: Former Executive Director
28. CONCLUDING REMARKS
29. APPENDIX I: TABULATED DATA
30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
31. APPENDIX III: LIST OF FUNDING AND INVESTMENTS
Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Clinical Trial Analysis
Figure 5.3 Executive Summary: Funding and Investments
Figure 5.4 Executive Summary: Patent Analysis
Figure 5.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Strategies Employed for the Redirection of T-Cells
Figure 6.2 T-Cell Manufacturing: General Procedure
Figure 6.3 Development History of CAR-T cells
Figure 6.4 Structure of Chimeric Antigen Receptor
Figure 6.5 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 6.6 CAR-T Cell Therapies: Development Process
Figure 6.7 Challenges Associated with CAR-T-Cell Therapies
Figure 7.1 CAR-T Cell Therapies: Distribution by Stage of Development
Figure 7.2 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 7.3 CAR-T Cell Therapies: Distribution by Target Antigen
Figure 7.4 CAR-T Cell Therapies: Distribution by Target Indication
Figure 7.5 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 7.6 CAR-T Cell Therapies: Distribution by Stage of Development and Therapeutic Area
Figure 7.7 CAR-T Cell Therapies: Distribution by Source of T-cells
Figure 7.8 CAR-T Cell Therapies: Distribution by Stage of Development and Source of T-cells
Figure 7.9 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 7.10 CAR-T Cell Therapies: Distribution by Dosage Regimen
Figure 7.11 CAR-T Cell Therapies: Distribution by Target Patient Population
Figure 7.12 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 7.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 7.14 CAR-T Cell Therapies Developers: Distribution by Year of Establishment
Figure 7.15 CAR-T Cell Therapies Developers: Distribution by Company Size
Figure 7.16 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Region)
Figure 7.17 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Country)
Figure 8.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 8.2 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 8.3 CAR-Construction: Distribution by Generation of CAR
Figure 8.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 8.5 CAR-Construction: Distribution by Type of Virus Used
Figure 8.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 8.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2017
Figure 9.2 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year, Since 2017
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2017
Figure 9.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 9.8 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 9.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 9.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 9.11 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 9.12 Clinical Trial Analysis: Distribution by Design Allocation
Figure 9.13 Leading Industry Players: Distribution by Number of Registered Trials
Figure 9.14 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 9.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 9.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 10.1 KOL Analysis: Distribution by Type of Organization
Figure 10.2 KOL Analysis: Distribution by Affiliated Organization
Figure 10.3 KOL Analysis: Distribution by Qualification
Figure 10.4 CAR-T Cell Therapies: Geographical Distribution of KOLs
Figure 10.5 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 10.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 10.7 Most Prominent KOLs: Distribution by RA Score
Figure 10.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 12.5 Most Popular Therapies: Distribution by Number of Partnerships
Figure 12.6 Most Active Industry Players: Distribution by Number of Partnerships
Figure 12.7 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 12.8 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 12.9 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 13.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2014
Figure 13.2 Funding and Investment Analysis: Distribution by Amount Invested, Since 2014 (USD Million)
Figure 13.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 13.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 13.5 Year-wise Distribution of Amount Invested by Type of Funding, Since 2018
Figure 13.6 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 13.7 Funding and Investment Analysis: Distribution of Funding Instances by Geography (Country)
Figure 13.8 Most Active Players: Distribution by Funding Instances
Figure 13.9 Leading Investors: Distribution by Number of Funding Instances
Figure 14.1 Patent Analysis: Distribution by Type of Patent
Figure 14.2 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, Since 2018
Figure 14.3 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Since 2017
Figure 14.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2018
Figure 14.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 14.6 Patent Analysis: Distribution by CPC Symbols
Figure 14.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 14.8 Leading Industry Players: Distribution by Number of Patents
Figure 14.9 Leading Non-industry Players: Distribution by Number of Patents
Figure 14.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 14.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 14.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 14.13 Patent Analysis: Distribution by Patent Age
Figure 14.14 CAR-T Cell Therapy: Patent Valuation
Figure 15.1 Steps for Manufacturing Cell Therapies
Figure 15.2 Centralized Manufacturing: Process Model
Figure 15.3 Decentralized Manufacturing: Process Model
Figure 15.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 15.5 Cell Therapy: Challenges and Drivers
Figure 15.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 15.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 15.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 16.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 17.1 CAR-T Cell Therapies: Market Drivers
Figure 17.2 CAR-T Cell Therapies: Market Restraints
Figure 17.3 CAR-T Cell Therapies: Market Opportunities
Figure 17.4 CAR-T Cell Therapies: Market Challenges
Figure 18.1 Global CAR-T Cell Therapy Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.2 Global CAR-T Cell Therapy Market: Conservative Scenario, Forecasted Estimates (till 2035) (USD Million)
Figure 18.3 Global CAR-T Cell Therapy Market: Optimistic Scenario, Forecasted Estimates (till 2035) (USD Million)
Figure 19.1 CAR-T Cell Therapy Market: Distribution by Product
Figure 19.2 CAR-T Cell Therapy Market for Abecma: Forecasted Estimates (till 2035)
Figure 19.3 CAR-T Cell Therapy Market for Breyanzi: Forecasted Estimates (till 2035)
Figure 19.4 CAR-T Cell Therapy Market for Carvykti: Forecasted Estimates (till 2035)
Figure 19.5 CAR-T Cell Therapy Market for Kymriah: Forecasted Estimates (till 2035)
Figure 19.6 CAR-T Cell Therapy Market for Tecartus: Forecasted Estimates (till 2035)
Figure 19.7 CAR-T Cell Therapy Market for Yescarta: Forecasted Estimates (till 2035)
Figure 20.1 CAR-T Cell Therapy Market: Distribution by Type of Therapy
Figure 20.2 CAR-T Cell Therapy Market for Autologous CAR-T Cell Therapy: Forecasted Estimates (till 2035)
Figure 20.3 CAR-T Cell Therapy Market for Allogeneic CAR-T Cell Therapy: Forecasted Estimates (till 2035)
Figure 21.1 CAR-T Cell Therapy Market: Distribution by Target Antigen
Figure 21.2 CAR-T Cell Therapy Market for CD19: Forecasted Estimates (till 2035) (USD Billion)
Figure 21.3 CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (till 2035) (USD Billion)
Figure 21.4 CAR-T Cell Therapy Market for CD20: Forecasted Estimates (till 2035) (USD Billion)
Figure 21.5 CAR-T Cell Therapy Market for CD19/22: Forecasted Estimates (till 2035) (USD Billion)
Figure 21.6 CAR-T Cell Therapy Market for Other Target Antigens: Forecasted Estimates (till 2035) (USD Billion)
Figure 22.1 CAR-T Cell Therapy Market: Distribution by Target Indication
Figure 22.2 CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (till 2035) (USD Billion)
Figure 22.3 CAR-T Cell Therapy Market for Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 22.4 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035) (USD Billion)
Figure 22.5 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 22.6 CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 22.7 CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 22.8 CAR-T Cell Therapy Market for Others: Forecasted Estimates (till 2035) (USD Billion)
Figure 23.1 CAR-T Cell Therapy Market: Distribution by Key Geographical Regions
Figure 23.2 CAR-T Cell Therapy Market in North America: Forecasted Estimates (till 2035) (USD Billion)
Figure 23.3 CAR-T Cell Therapy Market in Europe: Forecasted Estimates (till 2035) (USD Billion)
Figure 23.4 CAR-T Cell Therapy Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Billion)
Figure 23.5 CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (till 2035) (USD Billion)
Figure 23.6 CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Billion)
Figure 23.7 CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (till 2035) (USD Billion)
Figure 25.1 CAR-T Cell Therapy Market: Distribution by Key Players
Figure 25.2 CAR-T Cell Therapy Market: Bristol Myers Squibb Sales Forecast, till 2035 (USD Million)
Figure 25.3 CAR-T Cell Therapy Market: Janssen Sales Forecast, till 2035 (USD Million)
Figure 25.4 CAR-T Cell Therapy Market: Gilead Sciences Sales Forecast, till 2035 (USD Million)
Figure 25.5 CAR-T Cell Therapy Market: JW Therapeutics Sales Forecast, till 2035 (USD Million)
Figure 25.6 CAR-T Cell Therapy Market: Novartis Sales Forecast, till 2035 (USD Million)
Figure 26.1 Channels Used for Promotional Campaigns
Figure 26.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 26.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 26.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 26.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 26.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 26.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 26.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 26.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 26.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 26.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 26.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 26.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 26.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 26.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 26.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 26.17 Product Website Analysis: Abecma, Messages for Patients
Figure 26.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 26.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 26.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 26.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 28.1 Concluding Remarks: Market Landscape
Figure 28.2 Concluding Remarks: Clinical Trial Analysis
Figure 28.3 Concluding Remarks: Funding and Investment Analysis
Figure 28.4 Concluding Remarks: Patent Analysis
Figure 28.5 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 7.1 Key Characteristics of CAR-T Cells
Table 7.2 Comparison of First and Second-Generation CAR-Ts
Table 8.1 CAR-T Cell Therapies: Approved and Clinical Pipeline
Table 8.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-cell, Dosage Regimen, and Target Patient Population
Table 8.3 CAR-T Cell Therapy: Preclinical Pipeline
Table 8.4 List of CAR-T Cells Developers
Table 11.1 Leading CAR-T Cell Therapy Developers
Table 11.2 Autolus: Company Profile
Table 11.3 Bluebird Bio: Company Profile
Table 11.4 Bristol Myers Squibb: Company Profile
Table 11.5 CARsgen Therapeutics: Company Profile
Table 11.6 Cellectis: Company Profile
Table 11.7 Gilead Sciences: Company Profile
Table 11.8 Innovative Cellular Therapeutics: Company Profile
Table 11.9 Noile-Immune Biotech: Company Profile
Table 11.10 Novartis: Company Profile
Table 11.11 Sinobioway Cell Therapy: Company Profile
Table 11.12 Takara Bio: Company Profile
Table 11.13 Wellington Zhaotai Therapies: Company Profile
Table 12.1 CAR-T Cell Therapies: List of Partnerships and Collaborations, Since 2000
Table 13.1 CAR-T Cell Therapies: Funding and Investments, Since 2018
Table 13.2 CAR-T Cell Therapies: Summary of Investments
Table 14.1 Patent Analysis: Prominent CPC Sections
Table 14.2 Patent Analysis: Most Popular CPC Symbols
Table 14.3 Patent Analysis: List of Top CPC Symbols
Table 14.4 Patent Analysis: Summary of Benchmarking Analysis
Table 14.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 15.1 Assessment Strategies for Different Manufacturing Processes
Table 15.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 15.3 Cell Therapy Manufacturing: Companies with In-house Capabilities and Contract Manufacturers
Table 16.1 Price of Marketed Gene / Cell Therapies
Table 16.2 Price of Marketed Targeted Drugs
Table 16.3 CAR-T Cell Therapy: Expert Opinions on Pricing
Table 16.4 CAR-T Cell Therapy: Reimbursement Landscape
Table 24.1 CAR-T Cell Therapy: List of Forecasted Molecules
Table 29.1 CAR-T Cell Therapy: Distribution by Stage of Development
Table 29.2 CAR-T Cell Therapy: Distribution by Type of Therapy
Table 29.3 CAR-T Cell Therapy: Distribution by Target Antigen
Table 29.4 CAR-T Cell Therapy: Distribution by Target Indication
Table 29.5 CAR-T Cell Therapy: Distribution by Target Therapeutic Area
Table 29.6 CAR-T Cell Therapy: Distribution by Stage of Development and Therapeutic Area
Table 29.7 CAR-T Cell Therapy: Distribution by Source of T- cells
Table 29.8 CAR-T Cell Therapy: Distribution by Stage of Development and Source of T- cells
Table 29.9 CAR-T Cell Therapy: Distribution by Route of Administration
Table 29.10 CAR-T Cell Therapy: Distribution by Dosage Regimen
Table 29.11 CAR-T Cell Therapy: Distribution by Target Patient Population
Table 29.12 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 29.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 29.14 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 29.15 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 29.16 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region wise)
Table 29.17 CAR-T Cell Therapy: Distribution by Location of Headquarters (Country wise)
Table 29.18 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Table 29.19 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Table 29.20 CAR-Construction: Distribution by Generation of CAR
Table 29.21 CAR-Construction: Distribution by Type of scFv Antibody Used
Table 29.22 CAR-Construction: Distribution by Type of Virus Used
Table 29.23 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Table 29.24 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Table 29.25 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2017
Table 29.26 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2017
Table 29.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 29.28 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Table 29.29 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2017
Table 29.30 Clinical Trial Analysis: Distribution by Trial Status
Table 29.31 Clinical Trial Analysis: Distribution by Patient Gender
Table 29.32 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 29.33 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 29.34 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 29.35 Clinical Trial Analysis: Distribution by Trial Purpose
Table 29.36 Clinical Trial Analysis: Distribution by Design Allocation
Table 29.37 Leading Industry Players: Distribution by Number of Registered Trials
Table 29.38 Leading Non-industry Players: Distribution by Number of Registered Trials
Table 29.39 Clinical Trial Analysis: Distribution of Clinical Trials by Status and Geography
Table 29.40 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 29.41 KOL Analysis: Distribution by Type of Organization
Table 29.42 KOL Analysis: Distribution by Affiliated Organization
Table 29.43 KOL Analysis: Distribution by Qualification
Table 29.44 CAR-T Cell Therapies: Geographical Distribution of KOLs
Table 29.45 Most Prominent KOLs: Distribution by RA Score
Table 29.46 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 29.47 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Table 29.48 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.49 Partnerships and Collaborations: Distribution by Type of Partnership, Since 2015
Table 29.50 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 29.51 Partnerships and Collaborations: Distribution by Type of Partner
Table 29.52 Partnership and Collaborations: Year-Wise Distribution by Type of Partner
Table 29.53 Most Popular Therapies: Distribution by Number of Partnerships
Table 29.54 Most Active Industry Players: Distribution by Number of Partnerships
Table 29.55 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 29.56 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Table 29.57 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 29.58 Funding and Investment: Cumulative Distribution of Instances by Year, Since 2014
Table 29.59 Funding and Investment: Cumulative Distribution of Amount Invested by Year, Since 2014 (USD Million)
Table 29.60 Funding and Investment: Distribution of Instances by Type of Funding
Table 29.61 Funding and Investment: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 29.62 Funding and Investment: Distribution of Amount Invested by Year and Type of Funding
Table 29.63 Funding and Investment: Distribution by Geography (Region)
Table 29.64 Funding and Investment: Distribution by Geography (Country)
Table 29.65 Most Active Players: Distribution by Lead Investors
Table 29.66 Most Active Players: Distribution by Number of Funding Instances
Table 29.67 Patent Analysis: Distribution by Type of Patent
Table 29.68 Patent Analysis: Distribution by Patent Publication Year, Since 2018
Table 29.69 Patent Analysis: Distribution by Patent Application Year
Table 29.70 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2018
Table 29.71 Patent Analysis: Distribution by Patent Jurisdiction
Table 29.72 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 29.73 Leading Industry Players: Distribution by Number of Patents
Table 29.74 Leading Non-industry Players: Distribution by Number of Patents
Table 29.75 Leading Individual Assignees: Distribution by Number of Patents
Table 29.76 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Table 29.77 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Table 29.78 Patent Analysis: Distribution by Patent Age
Table 29.79 CAR-T Cell Therapy: Patent Valuation
Table 29.80 Global CAR-T Cell Therapy Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Table 29.81 Global CAR-T Cell Therapy Market: Conservative Scenario, Forecasted Estimates (till 2035) (USD Million)
Table 29.82 Global CAR-T Cell Therapy Market: Optimistic Scenario, Forecasted Estimates (till 2035) (USD Million)
Table 29.83 CAR-T Cell Therapy Market: Distribution by Product
Table 29.84 CAR-T Cell Therapy Market for Abecma: Forecasted Estimates (till 2035)
Table 29.85 CAR-T Cell Therapy Market for Breyanzi: Forecasted Estimates (till 2035)
Table 29.86 CAR-T Cell Therapy Market for Carvykti: Forecasted Estimates (till 2035)
Table 29.87 CAR-T Cell Therapy Market for Kymriah: Forecasted Estimates (till 2035)
Table 29.88 CAR-T Cell Therapy Market for Tecartus: Forecasted Estimates (till 2035)
Table 29.89 CAR-T Cell Therapy Market for Yescarta: Forecasted Estimates (till 2035)
Table 29.90 CAR-T Cell Therapy Market: Distribution by Type of Therapy
Table 29.91 CAR-T Cell Therapy Market for Autologous CAR-T Cell Therapy: Forecasted Estimates (till 2035)
Table 29.92 CAR-T Cell Therapy Market for Allogeneic CAR-T Cell Therapy: Forecasted Estimates (till 2035)
Table 29.93 CAR-T Cell Therapy Market: Distribution by Target Antigen
Table 29.94 CAR-T Cell Therapy Market for CD19: Forecasted Estimates (till 2035) (USD Million)
Table 29.95 CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (till 2035) (USD Million)
Table 29.96 CAR-T Cell Therapy Market for CD20: Forecasted Estimates (till 2035) (USD Million)
Table 29.97 CAR-T Cell Therapy Market for CD19/22: Forecasted Estimates (till 2035) (USD Million)
Table 29.98 CAR-T Cell Therapy Market for Other Target Antigens: Forecasted Estimates (till 2035) (USD Million)
Table 29.99 CAR-T Cell Therapy Market: Distribution by Target Indication (USD Million)
Table 29.100 CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (till 2035) (USD Million)
Table 29.101 CAR-T Cell Therapy Market for Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 29.102 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035) (USD Million)
Table 29.103 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 29.104 CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 29.105 CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 29.106 CAR-T Cell Therapy Market for Others: Forecasted Estimates (till 2035) (USD Million)
Table 29.107 CAR-T Cell Therapy Market: Distribution by Key Geographical Regions
Table 29.108 CAR-T Cell Therapy Market in North America: Forecasted Estimates (till 2035) (USD Million)
Table 29.109 CAR-T Cell Therapy Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Table 29.110 CAR-T Cell Therapy Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Table 29.111 CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Table 29.112 CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Million)
Table 29.113 CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (till 2035) (USD Million)
Table 29.114 CAR-T Cell Therapy Market: Distribution by Key Players
Table 29.115 CAR-T Cell Therapy Market: Bristol Myers Squibb Sales Forecast, till 2035 (USD Million)
Table 29.116 CAR-T Cell Therapy Market: Janssen Sales Forecast, till 2035 (USD Million)
Table 29.117 CAR-T Cell Therapy Market: Gilead Sciences Sales Forecast, till 2035 (USD Million)
Table 29.118 CAR-T Cell Therapy Market: JW Therapeutics Sales Forecast, till 2035 (USD Million)
Table 29.119 CAR-T Cell Therapy Market: Novartis Sales Forecast, till 2035 (USD Million)